Key result
GAPDH binders hydroxynonenal, -(-)deprenyl, and PGL-135 reduced aggregation and cytotoxicity in cell and fly models of Spinocerebellar ataxia.
A novel screening assay successfully identified GAPDH binders that reduce aggregation and cytotoxicity in preclinical models of polyglutamine diseases.
Answers are grounded in this paper and cite their sources.
Should not yet alter SCA management; extends preclinical evidence for GAPDH binders in polyglutamine disease.
Proteins with long polyglutamine repeats form a complex with glyceraldehyde-3-phosphate dehydrogenase (GAPDH), which enhances aggregation and cytotoxicity in models of Huntington disease. The aim of this study was to develop a novel assay for the screening of anti-aggregation compounds with a focus on the aggregation-promoting capacity of GAPDH. The assay includes a pure Q58 polyglutamine fragment, GAPDH, and a transglutaminase that links the two proteins. The feasibility of the new assay was verified using two GAPDH binders, hydroxynonenal and -(-)deprenyl, and the benzothiazole derivative PGL-135 which exhibits anti-aggregation effect. All three substances were shown to reduce aggregation and cytotoxicity in the cell and in the fly model of Spinocerebellar ataxia.
No takes yet. Share an insight, caveat, or question.
Lazarev et al. (2015) studied Polyglutamine diseases. GAPDH binders (hydroxynonenal, -(-)deprenyl, PGL-135) was evaluated on Aggregation and cytotoxicity. GAPDH binders hydroxynonenal, -(-)deprenyl, and PGL-135 reduced aggregation and cytotoxicity in cell and fly models of Spinocerebellar ataxia.
Synapse has enriched 10 related papers. Consider them for comparative context: